Massachusetts Financial Services Co. MA Sells 4,331 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Massachusetts Financial Services Co. MA trimmed its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 2.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 178,932 shares of the company’s stock after selling 4,331 shares during the period. Massachusetts Financial Services Co. MA owned about 0.12% of MiMedx Group worth $1,057,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Paradigm Capital Management Inc. NY lifted its holdings in MiMedx Group by 6.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock worth $28,879,000 after buying an additional 258,700 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after acquiring an additional 413,443 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after acquiring an additional 770,744 shares during the period. Royce & Associates LP boosted its holdings in MiMedx Group by 5.3% in the third quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock valued at $5,750,000 after acquiring an additional 48,539 shares in the last quarter. Finally, Millennium Management LLC increased its position in MiMedx Group by 339.9% during the 2nd quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock valued at $6,164,000 after purchasing an additional 687,267 shares during the period. 79.15% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MDXG. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a research note on Thursday, August 1st. StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Finally, Craig Hallum decreased their target price on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, MiMedx Group currently has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $9.43 on Thursday. The company has a 50 day simple moving average of $6.79 and a two-hundred day simple moving average of $6.88. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.64. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of 17.15 and a beta of 1.94. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.